Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Study symbols : Pfe save search
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain
Published: 2024-02-26 (Crawled : 00:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: -1.77%
TNXP | $0.159 1.27% 1.26% 1.1M
|
Health Technology
|
| O: 4.32%
H: 7.17%
C: 2.5%
drug fibromyalgia study
Anti-inflammatory Therapeutics Market Size to Hit US$ 149.5 billion by 2031 | Exclusive Study by Transparency Market Research
Published: 2023-10-30 (Crawled : 09:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: -4.67%
H: 4.9%
C: 4.9%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.43%
H: 1.46%
C: 1.03%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 1.69%
H: 0.25%
C: -0.07%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.39%
H: 0.79%
C: 0.64%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 2.29%
H: 0.44%
C: -0.23%
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 2.87%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
research therapeutics study market
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
Published: 2023-03-16 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -0.18%
H: 0.25%
C: 0.25%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.63%
H: 0.41%
C: -1.29%
xtandi cancer plus study
Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint
Published: 2023-03-13 (Crawled : 00:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.01%
H: 0.43%
C: 0.29%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.48%
H: 0.25%
C: -0.37%
xtandi china study
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
Published: 2023-02-16 (Crawled : 16:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.39%
H: 0.07%
C: -0.46%
talzenna positive study
Everest Medicines Announces Top-line Data from Phase I Study of EVER206 on Healthy Subjects in China
Published: 2023-01-17 (Crawled : 00:00) - prnewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -1.16%
H: 0.67%
C: -1.2%
ever206 china study
HIV Clinical Trials Market Research Report by Phase, Study Design, Sponsor, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-12-26 (Crawled : 13:20) - prnewswire.com
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
| Email alert
Add to watchlist
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
| Email alert
Add to watchlist
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
| Email alert
Add to watchlist
SYNH | $42.98 0.0% 7.4M
|
Health Services
| Email alert
Add to watchlist
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
| Email alert
Add to watchlist
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
covid-19 trials research global report hiv impact study market
Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model Myriad Genetics, Inc., a leader in genetic testing and preci...
Published: 2022-12-09 (Crawled : 13:00) - biospace.com/
SXT | $69.14 1.33% 0.0% 190K
|
Distribution Services
|
| O: -0.42%
H: 0.97%
C: -0.33%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.06%
H: 2.11%
C: -0.06%
TRIB | $1.81 -3.72% -3.87% 5.7K
|
Health Technology
|
| O: -1.56%
H: 1.58%
C: -1.75%
REPL | $6.47 -7.17% -7.73% 870K
|
Health Technology
|
| O: -0.25%
H: 5.25%
C: 4.17%
MYGN F | $18.515 0.03% 0.03% 490K
|
Health Technology
|
| O: -0.67%
H: 1.39%
C: -2.69%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.19%
H: 0.77%
C: -0.77%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -1.45%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.05%
H: 0.75%
C: -0.83%
APM | $5.9 9.87% 8.98% 37K
|
Health Technology
|
| O: -16.14%
H: 19.24%
C: 14.67%
risk breast genetic cancer study
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
Published: 2022-11-16 (Crawled : 00:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.22%
H: 0.0%
C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.52%
H: 1.45%
C: 1.11%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -2.28%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -1.45%
H: 2.36%
C: 2.31%
covid-19 candidate vaccine study
Macular Degeneration Treatment Market to Surpass US$ 21.1 Bn by 2031: TMR Study
Published: 2022-09-21 (Crawled : 02:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.98%
H: 0.0%
C: -1.99%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.09%
H: 0.38%
C: -1.99%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.73%
H: 0.04%
C: -1.85%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.47%
H: 1.24%
C: -2.32%
treatment macular study market
Pfizer Invites Public to View and Listen to Webcast of Analyst and Investor Call to Review Oral GLP-1 Data Presented at European Association for the Study of Diabetes (EASD) 2022
Published: 2022-09-14 (Crawled : 17:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.02%
H: 0.45%
C: -0.11%
review diabetes study
Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
Published: 2022-09-14 (Crawled : 11:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.02%
H: 0.45%
C: -0.11%
vaccine influenza study
Menopausal Hot Flashes Treatment Market Estimated to Rise at CAGR of 6% from 2019 to 2027, TMR Study
Published: 2022-08-25 (Crawled : 14:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: -1.29%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.19%
H: 0.9%
C: 0.8%
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.18%
H: 1.45%
C: 1.44%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.28%
H: 0.13%
C: 0.04%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.0%
H: 0.63%
C: 0.6%
treatment study market
Atopic Dermatitis Drugs Market to Rise at a CAGR of 14.7% during Forecast Period, observes TMR Study
Published: 2022-08-23 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.98%
H: 0.21%
C: -0.85%
BHC | $8.69 1.05% 0.0% 2.9M
|
Health Technology
|
| O: -0.89%
H: 0.54%
C: -5.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
dermatitis study market
Red Biotechnology Market to Exceed US$ 609.6 Bn by 2031: TMR Study
Published: 2022-08-19 (Crawled : 14:00) - prnewswire.com
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.04%
H: 0.12%
C: -2.22%
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: -2.05%
H: 0.29%
C: 0.07%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.54%
H: 1.24%
C: 0.63%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.01%
H: 2.09%
C: 1.58%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -0.62%
H: 0.57%
C: -0.42%
GILD | News | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: -0.25%
H: 1.19%
C: 0.49%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.78%
H: 0.49%
C: 0.22%
study market
Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants
Published: 2022-08-12 (Crawled : 11:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.54%
H: 3.79%
C: 3.21%
vaccine positive results study pneumococcal
Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Published: 2022-08-08 (Crawled : 21:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.36%
H: 0.72%
C: 0.06%
vla15 valneva candidate disease vaccine study
ViiV Healthcare Announces New Data at AIDS 2022 From Unblinded Phase of HPTN 084 Study in Women in Sub-Saharan Africa Showing Continued Superior Efficacy of Injectable Cabotegravir Long-Acting for PrEP Over Daily, Oral TDF/FTC Tablets
Published: 2022-07-28 (Crawled : 15:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -2.13%
H: 2.92%
C: -0.25%
women study africa
Pfizer and BioNTech Advance COVID-19 Vaccine Strategy With Study Start of Next-Generation Vaccine Candidate Based on Enhanced Spike Protein Design
Published: 2022-07-27 (Crawled : 11:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.69%
H: 0.61%
C: 0.02%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.24%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -2.28%
covid-19 candidate vaccine study
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.